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Abstract 
Immune checkpoint inhibitors have led to considerable therapy improvement in 
cancer patients. Autoimmune side effects including skin reactions are frequently 
observed. In melanoma those include rash and vitiligo and were shown to be 
associated with a prolonged overall survival. Little is known about skin reactions in 
NSCLC patients during immunotherapy. 
Here, we retrospectively investigated immune-related adverse skin reactions (irAEs) 
in 40 patients with metastatic non-small cell lung cancer (NSCLC) treated with the 
anti PD-1 antibody nivolumab. 7 out of 40 patients (17%) developed an irAEs.  
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Skin irAEs correlated with tumor responses in 5 of 12 responders (42%) as 
compared to 2 of 27 non-responders (7%). Histologically, scaly plaques showed 
dermatitis consisting mainly of lymphocytes. 
We observed a positive correlation between skin irAEs and tumor responses in 
patients with NSCLC treated with nivolumab. Patterns of lymphocytic skin infiltration 
differed depending on the histological tumor subtype (adenocarcinoma versus 
squamous cell carcinoma NSCLC). 
Key words 
immunotherapy, anti-PD1, non-small cell lung cancer, dermatology, pathology 
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Introduction 
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung 
cancers and can be divided into two major histological subtypes: adenocarcinoma 
(AC) and squamous cell carcinoma (SCC). Standard first-line treatment of metastatic 
disease consists of platinum-based chemotherapy. In selected molecular-defined 
subgroups the first-line therapy is a targeted therapy using tyrosine kinase inhibitors 
(TKI). 1  
The introduction of immunotherapy has significantly improved therapy outcome. Two 
phase III trials with the anti-PD1 (anti-programmed death 1 receptor) antibody 
nivolumab led to its approval in 2015 after it had been approved for metastatic 
melanoma in 2014. 2-5  
PD1-checkpoint inhibitors block the interaction between PD1-receptors on T-cells 
and their ligand PD-L1. Blocking PD1-receptors enhances T-cell response against 
cancer cells. 6 In turn, activated T-cells can cause autoimmune-mediated side 
effects, such as skin rash, colitis, hepatitis or pneumonitis. These are generally 
manageable and reversible in most cases. Rash and pruritus are frequent immune-
related dermatologic adverse reactions (skin irAEs) during immunotherapy, which 
have been reported to occur in up to 25 % of melanoma patients. 4, 5, 7, 8 Toxicity data 
for anti-PD1 approval in NSCLC reports skin irAEs in approximately 10% of patients 
2, 3, 9, but as of recently higher rates have emerged. 10, 11 Grading of toxicity is 
commonly classified according to Common Terminology Criteria for Adverse Events 
(CTCAE version 4.0). Management of skin irAEs includes symptomatic treatment 
with antihistamines and topical steroids, but may be complemented with systemic 
immunosuppression in severe cases. 12 Previous data strongly suggest that skin 
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irAEs under anti-PD1 therapy are associated with increased overall survival (OS) 
and may serve as a parameter to predict a better therapy response. 13, 14  
The aim of this study is to i) characterize skin irAEs in patients with advanced lung 
cancer treated with nivolumab and ii) to specify the pattern of T-cell infiltration in 
biopsies of these skin lesions. 
Materials and Methods 
Assessing tumor response to therapy with nivolumab and skin irAEs 
After approval by the local ethics committee (EKSG Nr. 16/059) and in accordance 
with the Declaration of Helsinki Principles, we retrospectively analyzed patients with 
metastatic NSCLC treated with nivolumab (Opdivo®, Bristol-Meyers Squibb, SA). 
Treatment was initiated between January 2015 and February 2016 within an early 
access program at the Cantonal Hospital St. Gallen (Switzerland). Patients had at 
least one treatment cycle with the standard dose of 3 mg/kg i.v. over 60 minutes 
every two weeks. Tumor response was evaluated using computed tomography (CT) 
and was categorized as progressive disease (PD), stable disease (SD) and partial 
remission (PR) according to RECIST criteria 1.1. 16 We further assessed results of 
skin examinations that had been performed during patient visits and classified skin 
irAEs according to clinical dermatological criteria.  
Immunohistochemistry analysis 
Histology of punch biopsies from untreated skin rash was available from 4 patients, 
of which 2 had SCC and 2 had AC. Biopsies of the SCC patients were taken from 
the right forearm and right lower limb and of the AC patients from the right cheek and 
left lower limb (one each, respectively).  All punch biopsies had been performed by a 
dermatologist. Histopathological analyses were conducted independently by a 
pathologist and a dermatopathologist. From each representative paraffin-embedded 
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skin block four microns-thick sections were obtained for HE and 
immunohistochemistry (IHC) staining (CD3, CD4 and CD8). For each sample we 
determined lymphocyte counts in the epidermis and dermis per 1mm2 (= 4 random 
high power fields). 
Results 
Tumor response and skin irAEs in NSCLC under nivolumab therapy  
We identified 41 patients treated with at least one single dose of nivolumab. One 
patient was excluded because consent was refused. Patient age ranged from 46 to 
88 years (mean 65 years). 22 (55%) were male and 18 (45%) female (Table 1). On 
average, the 40 patients were treated with 7 cycles, ranging from 1 to 25 cycles. The 
interval between treatment initiation and appearance of a skin irAE was 3 cycles. 
23 (57%) of our patients had ACs, 14 (35%) SCCs and in 3 (8%) the tumor displayed 
features of both subtypes (mixed subtype). 27 (67%) showed disease progression 
under nivolumab therapy. We were unable to assess disease progression in one 
individual because the patient had died due to ileus before a re-staging could be 
performed.  
7 (17%) developed a skin irAE under treatment. All skin reactions were classified 
grade I or II (CTCAE 4.0). In this subpopulation 4 (57%) were scaly plaques (Figure 
1A/B) and 3 (43%) intense pruritus without visible skin lesions. Only 2 (29%) with 
skin irAEs had PD, as opposed to all patients, where the majority had PD. 
Furthermore, skin irAEs correlated with tumor responses in 5 of 12 responders 
(42%) as compared to 2 of 27 non-responders (7%). 
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Immune infiltrate patterns of skin rash under nivolumab therapy correlates 
with NSCLC subtype  
Immunohistochemistry of the skin biopsies showed that the distribution of CD3+ T-
cells in the inflammatory skin infiltrate was dependent on the cancer subtype (Figure 
1F/G). We observed an analogous cell distribution pattern among cytotoxic CD8+ T-
cells. In patients with SCCs the lymphocyte infiltrates were more prominent above 
the basal cell membrane whereas patients with ACs showed CD8+ T-cell infiltrates 
more accentuated towards the dermis (Figure 2A-D). Quantification of the T-cell 
infiltrates further supported this observation: the ratios of CD8+ T-cells found in the 
epidermis compared to all CD8+ T-cells of two patients with SCCs were 22% and 
44%, respectively, while in two patients with ACs the ratios were 3% and 10%, 
respectively (Figure 2A-D). 
Discussion 
Autoimmune-mediated side effects affecting different organs are known to occur 
during treatment with immunotherapy. In NSCLC patients treated with nivolumab 
skin eruptions and pruritus have been reported in approximately 10% or higher.  2, 3, 
9-11 This was also reflected by our study. Several authors reported higher numbers of 
skin irAEs in melanoma patients under nivolumab treatment. 4, 5, 7, 8  
An association between appearance of skin irAEs and overall survival in melanoma 
has been reported. 13-15, 17 Similarly, our data suggests an association between skin 
irAEs and tumor response. The histological analysis of the rashes on the one hand 
allowed us to rule out clinical differential diagnoses of eczema and psoriasis and on 
the other hand revealed that the rashes were characterized by an inflammation rich 
in CD3+ T-lymphocytes. Immunophenotypisation showed analogous lichenoid 
patterns among rashes with SCC-patients. They displayed distinct epidermotropic 
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inflammatory infiltrates consisting mainly of cytotoxic CD8+ T-cells. Civatte bodies 
(damaged basal keratinocytes) suggest that these lymphocytes induce keratinocyte 
death. From these findings we deduct that the skin of these patients harbored auto-
immune T-cells that were activated and attacked healthy keratinocytes. It is further 
possible that tumor-specific T-cells, activated by anti-PD1 treatment, migrated to the 
skin. Since T-cells can migrate and scan antigens presented by MHC-I molecules on 
all body cells, they can recognize the same antigen at any body site. It is possible 
that keratinocytes express antigens that are identical or very similar to those of the 
tumor, known as antigen sharing or as molecular mimicry, respectively. 18 In our 
point of view, antigen sharing can presently be considered the most likely cause, as 
lung SCCs and keratinocytes both produce similar proteins including several 
cytokeratins. 19 In  contrast, the histology of skin rashes of AC patients showed 
inflammation with lymphocytes located predominantly below the basal cell 
membrane within the dermis, which contains glandular structures (e.g. eccrine sweat 
glands). Those may share antigens with lung ACs. 
Limitation of the study was the small sample size of 40 patients. One needs to keep 
in mind that immunotherapy for treating NLCSCs has only recently been approved 
and was provided through the early access program. We are confident that the 
recent approval now enables broader access to immunotherapy, which will allow our 
findings to be compared to future investigations from larger sample sizes. 
In conclusion, our results suggest that the tissue tropism of lymphocytes in skin 
irAEs may be more specific than previously known, opening new opportunities for 
elucidating the underlying molecular mechanisms. 
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Table 1. Patient characteristics.  
Parameter     
Patient number   40 
Age (years)  Mean 65.5 
Range 46 - 88 
Gender  Male 22 
Female 18 
Histological type  Adenocarcinoma 23 
Squamous cell carcinoma 14 
Mixed type 3 
Nivolumab cycles  Mean 7 
Range 1 - 25 
Nivolumab cycles until 
adverse skin reaction 
 Mean 3 
Range 2 - 8 
Type of adverse skin 
reaction 
 Plaques 4 
Pruritus 3 
Tumor response in patients 
with adverse skin reaction 
 Response 5 
No response 2 
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Table 2. Clinical presentation and histology of 4 patients 
Patie
nt 
Gender, age in 
years 
Onset (after 
cycles/days) 
NSCL
Ca 
Clinical 
presentati
on 
Histology 
1 m; 69 2/15 SCCb Focal 
plaques 
with thick 
squamae 
on the 
extremities
, with 
burning 
sensation, 
no 
mucosal 
involveme
nt 
Lichenoid 
dermatitis 
with 
interface-
component 
at the 
dermo-
epidermal 
junction 
and CD8+ 
cell 
infiltrate in 
the 
epidermis 
and 
dermis. 
2 m; 68 2/37 SCC Focal 
plaques 
with thick 
squamae 
on the 
Lichenoid 
dermatitis 
with 
interface-
component 
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extremities
, mild 
pruritus 
and 
burning, 
no 
mucosal 
involveme
nt 
at the 
dermo-
epidermal 
junction. 
CD8+ cell 
infiltrate 
visible in 
the 
epidermis, 
with 
apoptotic 
keratinocyt
es, and the 
dermis. 
3 f; 86 1/7 ACc Focal 
scaly 
plaques 
on the 
extremities 
with 
pruritus, 
no 
mucosal 
involveme
nt 
Spongiotic 
dermatitis 
with 
accumulati
on of 
CD8+ T-
cells below 
the basal 
cell 
membrane
, sparse 
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aNSCLC: non-small cell lung cancer 
bAC: adenocarcinoma 
cSCC: squamous cell carcinoma 
  
affection of 
epidermis. 
4 m; 59 8/111 AC Focal 
erythemat
ous 
plaques 
with fine 
scaling on 
the upper 
face, no 
mucosal 
involveme
nt 
Lymphocyt
ic infiltrate 
with 
accentuati
on in the 
deep 
dermis. 
Sparse 
interface 
component 
with 
sporadic 
vacuolizati
on of basal 
keratinocyt
es. 
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Figure 1. a. Skin rash under nivolumab in a patient with squamous cell carcinoma 
(SCC) of the lung or b. adenocarcinoma (AC) of the lung. c. Histopathology shows 
an inflammatory infiltrate migrating into the epidermis in SCC patients (hematoxylin 
eosin (HE), 100x). d. Apoptotic keratinocytes, also called Civatte bodies, are visible 
in SCC patients (HE, 200x). e. The infiltrate does not seem to migrate in AC patients 
(HE, 100x). f. Immunohistochemistry shows that the inflammation consists mainly of 
lymphocytes in both SCC (CD3, 100x) and g. AC (CD3, 100x) patients. The basal 
cell membrane is outlined in red.  
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Figure 2. a.b. Immunohistochemistry with a CD8 stain of skin rash of 2 SCC patients 
(CD8, 100x) and c.d. 2 AC patients (CD8, 100x). The migration of the inflammation 
appears to differ among tumor subtypes. The number in the upper right corner of 
each panel indicates the percentage of CD8+ T-cells in the epidermis compared to 
the total of CD8+ T-cells of 4 high-power fields. They illustrate that the relative CD8+ 
T-cell count in the epidermis is greater among 2 SCC patients than among 2 AC 
patients. 
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Background 
 
The clinical application of checkpoint inhibitors (CIs), or immunotherapy, marks a 
fundamental advancement in cancer therapy and management.1 Prospective trials 
with large-scale cohorts comparing treatment of NSCLC with CIs to chemotherapy 
have shown that CIs result in better progression free survival and overall survival.2-4 
Data also suggests that progression-free survival can be sustained over years.4 
 
Cytotoxic T-cells hold a crucial role in recognizing and fighting malignant cells. 
However, they need to be susceptible to modulation to prevent them from exercising 
autoimmunity. One way of modulation is the expression of surface receptors that 
mediate their exhaustion and in effect suppress their activity. Examples of such 
receptors are cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) and 
Programmed Cell Death Protein 1 (PD-1). Some cancers, such as melanoma and 
non-small cell lung cancer (NSCLC), are capable of exploiting these modulatory 
mechanisms by producing ligands that cause T-cell suppression.  
T-cell activation requires two signals: first, binding of an antigen-MHC-complex to the 
surface T-cell receptor (TCR). Secondly, binding of ligands to a co-receptor, such as 
CD28. CD28 is responsible for early TCR-signaling amplification. It is counteracted 
by CTLA-4, a suppressive T-cell surface receptor that binds the same ligand as 
CD28. In conclusion, blocking CTLA-4 with the antibody ipilimumab promotes the 
ligand binding to CD28 and thus endogenous antitumor response. PD-1 is another 
example of a T-cell suppressing surface receptor and commonly found in peripheral 
tissues, thus causing an on-site suppression.5  
 
Despite these seemingly obvious mechanism, the tumor response rate to CI 
treatment is reportedly around 40%, even in the group of PD-L1 positive NSCLC only 
for reasons not yet fully understood.4 
Validated predictive factors for tumor response are still scarce and under 
investigation. In melanoma treatment, favorable baseline values seem to be a high 
relative Eosinophil count, high lymphocyte count, low LDH and no metastases other 
than soft tissue metastases.6 In NSCLC patients the response rate among patients 
with PD-L1 producing tumors is higher compared to those not producing PD-L1.4 A 
general association with cancer PD-L1 production and better response, however, 
remains controversial since it seems to vary among tumor types.7 
 
In Switzerland, ipilimumab (anti-CTLA-4), pembrolizumab and nivolumab (both anti-
PD1) are admitted as treatment options in metastasized melanoma and nivolumab 
for second-line treatment of NSCLC. 
 
Since CIs increase immune system activity, they lead to immune-related adverse 
events (irAEs). Examples are colitis, endocrine disorders and skin disorders. 
Common skin irAEs are pruritus and rash.8 Among all organs the skin is most 
commonly affected 9 and in case of anti-CTLA-4 skin irAEs appear earliest compared 
to other organs.10 Fortunately, skin irAEs tend to be mild, usually reaching a severity 
on the Common Toxicology Criteria of Adverse Events (CTCAE) of 1-2.11 Low-
severity skin irAEs are well manageable with topical corticosteroids, rarely 
necessitating a break from therapy. In the rare case of skin irAEs of CTCAE grades 
3-4 a pause of therapy and intervention with systemic immunosuppressants, such as 
corticosteroids, are recommended.12 
 
In melanoma patients under immunotherapy, the histology of skin rashes has been 
investigated. Most of them were characterized by a lichenoid inflammation pattern, 
which suggests involvement of cytotoxic T-cells.13, 14 The appearance of vitiligo 
during CI treatment of melanoma is also regarded a skin irAE. Developing vitiligo has 
been attributed to antigen sharing: T-cells identify and target antigens in melanoma 
that may also naturally occur in  normal melanocytes.15 Therefore, vitiligo 
development in melanoma patients may be a surrogate parameter for a favorable 
immune system reaction against melanoma antigens and may thus be associated 
with a better outcome.16, 17 
 
To the knowledge of the authors, a systematic histopathologic characterization of 
skin rashes in a cohort of NSCLC patients under CI-therapy has not yet been 
published.  
 
Hypothesis 
 
NSCLCs can roughly be subdivided into two subtypes: squamous NSCLC (sNSCLC) 
and adenocarcinoma-type NSCLC (aNSCLC).18 This made skin rashes induced by 
CIs for NSCLC treatment suitable candidates for exploring the hypothesis, that skin 
rashes may be caused by sharing autoantigens in tumor and healthy tissue. 
sNSCLC mostly likely contains antigens that are found in the epidermis. Therefore, 
the authors expected an inflammatory infiltrate consisting of CD8+ T-Cells in the 
epidermis. aNSCLC, on the other hand, most likely carries antigens found in the 
dermis since this is where glandular structures are rooted.19 The authors 
hypothesized that skin rashes in patients with aNSCLC T-cells will more likely be 
found below the basement membrane in the dermis. 
 
The purpose of this study was to 
 
1. characterize skin irAEs in NSCLC patients treated with nivolumab 
2. assess if the occurrence of skin irAEs correlated with disease progression and 
3. to examine histological patterns of inflammation in sNSCLC and aNSCLC to 
elaborate on the possibility of a different T-cell distribution.  
Conclusions 
 
We observed epidermotropism of cytotoxic CD8+ T-cells into the epidermis in 2 
patients with sNSCLCs. This effect was not observed in 2 patients with aNSCLCs. 
This supports the thesis that antigen sharing in skin and tumor could be crucial in 
developing skin irAEs, which are rather collateral damage than toxicity. 
Characterization of skin irAEs and relation to survival can be read in the “Results” 
section of the paper. 
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